$129.63
4.29% yesterday
Nasdaq, Jul 16, 10:00 pm CET
ISIN
US53220K5048
Symbol
LGND

Ligand Pharmaceuticals Incorporated Stock price

$129.63
+14.62 12.71% 1M
+18.55 16.70% 6M
+22.48 20.98% YTD
+30.68 31.01% 1Y
+74.14 133.61% 3Y
+56.01 76.08% 5Y
+65.40 101.82% 10Y
+121.54 1,502.35% 20Y
Nasdaq, Closing price Wed, Jul 16 2025
+5.33 4.29%
ISIN
US53220K5048
Symbol
LGND
Sector
Industry

Key metrics

Basic
Market capitalization
$2.5b
Enterprise Value
$2.3b
Net debt
positive
Cash
$208.9m
Shares outstanding
19.0m
Valuation (TTM | estimate)
P/E
negative | 19.9
P/S
13.8 | 12.1
EV/Sales
12.6 | 11.1
EV/FCF
45.8
P/B
3.1
Financial Health
Equity Ratio
88.1%
Return on Equity
-0.5%
ROCE
-5.5%
ROIC
-5.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$181.5m | $197.9m
EBITDA
$-13.9m | $78.0m
EBIT
$-46.9m | $35.6m
Net Income
$-132.2m | $118.7m
Free Cash Flow
$50.1m
Growth (TTM | estimate)
Revenue
53.4% | 18.4%
EBITDA
-143.4% | 39.1%
EBIT
-3,278.1% | 54.4%
Net Income
-237.4% | 3,044.7%
Free Cash Flow
283.5%
Margin (TTM | estimate)
Gross
92.8%
EBITDA
-7.6% | 39.4%
EBIT
-25.8%
Net
-72.8% | 60.0%
Free Cash Flow
27.6%
More
EPS
$-7.0
FCF per Share
$2.6
Short interest
7.3%
Employees
68
Rev per Employee
$2.5m
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
92%
Hold
8%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
181 181
53% 53%
100%
- Direct Costs 13 13
35% 35%
7%
168 168
55% 55%
93%
- Selling and Administrative Expenses 87 87
64% 64%
48%
- Research and Development Expense 66 66
175% 175%
36%
-14 -14
143% 143%
-8%
- Depreciation and Amortization 33 33
1% 1%
18%
EBIT (Operating Income) EBIT -47 -47
3,278% 3,278%
-26%
Net Profit -132 -132
237% 237%
-73%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

Neutral
GlobeNewsWire
7 days ago
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum.
Neutral
GlobeNewsWire
15 days ago
Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, Ligand has invested $18 million in the combined company and is entitled to a 13% royalty on worldwide sales of ZELSUVMI Pelthos will commence trading on the NYSE American exchange under the new ticker symbol “PTHS” on July 2, 2025 JUPITER, Fla., July 02...
Neutral
GlobeNewsWire
15 days ago
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name “Pelthos Therapeutics Inc.” and will trade on the NYSE American exchange under the ticker symbol “PTHS” starting on July 2,...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today